KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) CEO Benjamin L. Palleiko sold 7,352 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $12.19, for a total value of $89,620.88. Following the completion of the transaction, the chief executive officer now owns 250,800 shares of the company’s stock, valued at approximately $3,057,252. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
KalVista Pharmaceuticals Trading Down 5.6 %
Shares of NASDAQ KALV traded down $0.66 during mid-day trading on Tuesday, reaching $11.21. The company had a trading volume of 556,002 shares, compared to its average volume of 501,665. The firm has a 50 day simple moving average of $13.16 and a two-hundred day simple moving average of $12.39. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.21 and a 52-week high of $16.88. The stock has a market cap of $484.50 million, a P/E ratio of -3.30 and a beta of 0.89.
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last issued its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.04. On average, equities analysts expect that KalVista Pharmaceuticals, Inc. will post -3.57 EPS for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of research firms have weighed in on KALV. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday. Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday.
Get Our Latest Stock Analysis on KALV
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Further Reading
- Five stocks we like better than KalVista Pharmaceuticals
- Best Aerospace Stocks Investing
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- What is a Bond Market Holiday? How to Invest and Trade
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- Are Penny Stocks a Good Fit for Your Portfolio?
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.